Medtronic, Inc. (NYSE: MDT), a Minneapolis-based medical technology company, has announced the preliminary settlement of the securities class action pending against the company in the D. of Minnesota. The case, originally filed in 2008, stems from allegations that the company and certain of its officers made materially false statements regarding the extent to which revenue from one of its products, the Infuse bone graft, depended on applications not approved by the FDA (i.e., “off-label” uses).
The settlement is for $85 million. Reuters has an article. The 10b-5 Daily previously has posted about the court’s decision to certify the proposed class over the defendants’ objection that the plaintiffs could not adequately represent the class “because of alleged misrepresentations counsel made in the Amended Complaint regarding the testimony of the confidential witnesses.”